METHOD FOR PREDICTION OF TIMOLOL TREATMENT EFFECTIVENESS OF PRIMARY OPEN-ANGLE GLAUCOMA Russian patent published in 2019 - IPC G01N33/48 C12Q1/6806 C12Q1/686 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and is intended for prediction of clinical effectiveness of timolol primary open-angle glaucoma (POAG). Method involves taking samples of buccal scrapes, recovering genomic DNA, allele-specific polymerase chain reaction for genotyping by polymorphous locus GSTP1^Ilel05Val (rs1695) glutathione-8-transferase-P1 gene GSTP1 patients diagnosed with "primary open-angle glaucoma" of Russian nationality. In genotype carriers GSTP1^Ilel05Ile predicting an ophtalmohypotensive response to timolol treatment equal to or greater than 20 %, with 5.63-fold probability, and in genotype carriers GSTP1^Ilel05Val ophtalmohypotensive response to timolol therapy of less than 20 % with 9.50-fold probability.

EFFECT: use of the invention enables predicting the clinical effectiveness of timolol POAG and to determine personalized therapeutic approach to patients, promoting maximum therapeutic ophthalmopotensive effect.

1 cl, 1 dwg, 2 tbl, 2 ex